The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis
Open accessAbstract
Summary Background Lumacaftor/ivacaftor combination therapy demonstrated clinical benefits in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. Pretreatment lung function is a confounding factor that potentially impacts the efficacy and safety of lumacaftor/ivacaftor therapy. Methods Two multinational, randomised, double-blind, placebo-controlled, parallel-group Phase 3 studies randomised patients to receive placebo or lumacaftor (600 mg once daily [qd] or 400 mg every 12 hours [q12h]) in combination with ivacaftor (250 mg q12h) for 24 weeks. Prespecified analyses of pooled efficacy and safety data by lung function, as measured by percent predicted forced expiratory volume in 1 second (ppFEV1), were performed for patients with baseline ppFEV1 <40 (n=81) and ≥40 (n=1016) and screening ppFEV1 <70 (n=730) and ≥70 (n=342). These studies were registered with ClinicalTrials.gov (NCT01807923 and NCT01807949). Findings The studies were conducted from April 2013 through April 2014. Improvements in the primary endpoint, absolute change from baseline at week 24 in ppFEV1, were observed with both lumacaftor/ivacaftor doses in the subgroup with baseline ppFEV1 <40 (least-squares mean difference versus placebo was 3∙7 and 3.3 percentage points for lumacaftor 600 mg qd/ivacaftor 250 mg q12h and lumacaftor 400 mg q12h/ivacaftor 250 mg q12h, respectively [p<0∙05] and in the subgroup with baseline ppFEV1 ≥40 (3∙3 and 2∙8 percentage points, respectively [p<0∙001]). Similar absolute improvements versus placebo in ppFEV1 were observed in subgroups with screening ppFEV1 <70 (3∙3 and 3∙3 percentage points for lumacaftor 600 mg qd/ivacaftor 250 mg q12h and lumacaftor 400 mg q12h/ivacaftor 250 mg q12h, respectively [p<0∙001]) and ≥70 (3∙3 and 1∙9 percentage points, respectively [p=0.002] and [p=0∙079]). Increases in BMI and reduction in number of pulmonary exacerbation events were observed in both LUM/IVA dose groups vs placebo across all lung function subgroups. Treatment was generally well tolerated, although the incidence of some respiratory adverse events was higher with active treatment than with placebo. Interpretation Lumacaftor/ivacaftor combination therapy benefits patients homozygous for Phe508del CFTR who have varying degrees of lung function impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Quittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., & Montgomery, A. B. (2009) · Chest · doi:10.1378/chest.08-1190 · Cited by 400
Self-citationIvacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation
Flume, P. A., Liou, T. G., Borowitz, D. S., Li, H., Yen, K., Ordoñez, C. L., & Geller, D. E. (2012) · Chest · doi:10.1378/chest.11-2672 · Cited by 338
Cited by
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis
Habib, A.-R. R., Kajbafzadeh, M., Desai, S., Yang, C. L., Skolnik, K., & Quon, B. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43652-2 · Cited by 98
Ren, C. L., Morgan, R. L., Oermann, C., Resnick, H. E., Brady, C., Campbell, A., DeNagel, R., Guill, M., Hoag, J., Lipton, A., et al. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201707-539ot · Cited by 74
Flume, P. A., Biner, R. F., Downey, D. G., Brown, C., Jain, M., Fischer, R., De Boeck, K., Sawicki, G. S., Chang, P., Paz-Diaz, H., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30510-5 · Cited by 52
Self-citation
Metadata
- Authors
- Elborn, J. S., Ramsey, B. W., Boyle, M. P., Konstan, M. W., Huang, X., Marigowda, G., Waltz, D., & Wainwright, C. E.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 4
- Issue
- 8
- Pages
- 617-626
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2419518172
- Cited by
- 165
- References
- 4
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. https://app.cochat.ai/papers/10.1016/s2213-2600(16)30121-7
- The paper
- Elborn, J. S., Ramsey, B. W., Boyle, M. P., Konstan, M. W., Huang, X., Marigowda, G., Waltz, D., & Wainwright, C. E. (2016). Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(16)30121-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.